Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GRK6 | P43250 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18462192 | 0.81 | CES1 (0.50) | MAOBMAOANPC1MAPTRAB9A | |
| SCHEMBL15297680 | 0.76 | — | — | |
| SCHEMBL4834533 | 0.75 | TSHR (0.49) | NPC1MAPTRAB9ACYP19A1ALDH1A1 | |
| SCHEMBL8164156 | 0.72 | GFER (1.00) | GFERMAOBMAOAMAPTTP53 | |
| SCHEMBL3482833 | 0.72 | GFER (1.00) | GFERMAOBMAOAMAPTTP53 | |
| SCHEMBL187043 | 0.72 | GFER (1.00) | GFERMAOBMAOAMAPTTP53 | |
| SCHEMBL4829470 | 0.71 | GAA (0.47) | MAOBMAOANPC1MAPTRAB9A | |
| SCHEMBL19276531 | 0.70 | HRH1 (0.38) | MAOACYP3A4CYP1A2CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL8653872 | 0.70 | GFER (0.93) | GFERMAOBMAOAMAPTCYP19A1 | |
| SCHEMBL14874672 | 0.69 | GFER (0.50) | GFERMAOBMAOANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3205645-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-9957251-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| EP-3205645-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-16 | — | — | EP | disclosed |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | US | disclosed |
| EP-2583965-B1 | HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-8937055-B2 | Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20130296276-A2 | HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130116214-A1 | HETEROCYCLIC RING COMPOUND | UJIKAWA OSAMU (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2583965-A1 | HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | GFER 575/4885MAOB 881/4885MAOA 1368/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | GFER 575/4885MAOB 881/4885MAOA 1368/4885 |
| US-20130116214-A1 | HETEROCYCLIC RING COMPOUND | FABP4, CPT1B, GPR119 | GFER 4043/4885MAOB 3932/4885MAOA 4185/4885 |
| US-20130296276-A2 | HETEROCYCLIC RING COMPOUND | FABP4, CPT1B, GPR119 | GFER 4043/4885MAOB 3932/4885MAOA 4185/4885 |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | CDK19, CDK9, CDK8 | GFER 4768/4885MAOB 3827/4885MAOA 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.